» Articles » PMID: 25813872

Outcome of Patients with Systemic Lupus Erythematosus on Chronic Dialysis: an Observational Study of Incident Patients of the French National Registry 2002-2012

Overview
Journal Lupus
Publisher Sage Publications
Specialty Rheumatology
Date 2015 Mar 28
PMID 25813872
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The objective of this article is to describe the outcome (mortality, kidney transplantation) of patients with systemic lupus erythematosus (SLE) on chronic dialysis.

Methods: The overall and cardiovascular (CV) mortality and access to kidney transplantation were studied in all SLE patients incident on chronic dialysis in France between 2002 and 2012 (REIN registry). They were compared to age- and sex-matched patients with diabetic nephropathy and with autosomal dominant polycystic kidney disease (PKD) on chronic dialysis.

Results: A total of 368 SLE patients were included in the national REIN registry between 2002 and 2012. Cumulative incidence of death was 16.9% at five years, with no difference between haemodialysis and peritoneal dialysis. Independent risk factors of death were age, past history of cardiovascular disease (CVD) and chronic respiratory insufficiency. At five years, CV and all-cause mortality in SLE patients were lower than in matched diabetic patients, but three-fold higher than in matched PKD patients. Access to the kidney transplant waiting list and to kidney transplantation was higher in SLE patients than in matched diabetic patients, but lower than in matched PKD patients.

Conclusions: SLE patients on chronic dialysis are a population at high risk of death influenced by CV burden and chronic respiratory failure, but not by the method of dialysis. Their outcome, in terms of mortality and access to kidney transplantation, is intermediate between diabetic patients and patients with PKD.

Citing Articles

Systemic Lupus Erythematosus in Hemodialysis: Survival Comparison and Mortality-Related Factors.

Lee H, Kang S Medicina (Kaunas). 2025; 61(1.

PMID: 39859137 PMC: 11767054. DOI: 10.3390/medicina61010155.


Long-term Outcomes of Lupus Nephritis in Comparison to Other CKD Etiologies.

Chrysostomou C, Faustini F, Gunnarsson I, Segelmark M, Carrero J, Barany P Kidney Int Rep. 2025; 10(1):157-168.

PMID: 39810755 PMC: 11725829. DOI: 10.1016/j.ekir.2024.10.021.


Peritoneal dialysis versus haemodialysis for people commencing dialysis.

Ethier I, Hayat A, Pei J, Hawley C, Johnson D, Francis R Cochrane Database Syst Rev. 2024; 6:CD013800.

PMID: 38899545 PMC: 11187793. DOI: 10.1002/14651858.CD013800.pub2.


Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?.

Jourde-Chiche N, Bobot M, Burtey S, Chiche L, Daugas E Kidney Int Rep. 2023; 8(8):1481-1488.

PMID: 37547513 PMC: 10403675. DOI: 10.1016/j.ekir.2023.05.012.


Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D RMD Open. 2020; 6(2).

PMID: 32699043 PMC: 7425195. DOI: 10.1136/rmdopen-2020-001263.